Compare DLHC & DRIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DLHC | DRIO |
|---|---|---|
| Founded | 1969 | 2011 |
| Country | United States | United States |
| Employees | 2300 | N/A |
| Industry | Business Services | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 58.0M | 56.8M |
| IPO Year | 2012 | 2013 |
| Metric | DLHC | DRIO |
|---|---|---|
| Price | $3.65 | $3.42 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $12.33 |
| AVG Volume (30 Days) | 12.0K | ★ 49.1K |
| Earning Date | 12-09-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 1559.02 |
| EPS | N/A | ★ 1.75 |
| Revenue | ★ $41,923,000.00 | $7,394,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $38.77 |
| P/E Ratio | ★ N/A | $1.99 |
| Revenue Growth | 2.57 | ★ 43.02 |
| 52 Week Low | $3.38 | $3.01 |
| 52 Week High | $8.09 | $14.77 |
| Indicator | DLHC | DRIO |
|---|---|---|
| Relative Strength Index (RSI) | 38.20 | 26.12 |
| Support Level | $3.61 | N/A |
| Resistance Level | $4.15 | $8.10 |
| Average True Range (ATR) | 0.16 | 0.65 |
| MACD | -0.03 | -0.13 |
| Stochastic Oscillator | 10.67 | 11.48 |
DLH Holdings Corp delivers health and readiness solutions for federal government customers through digital transformation and cyber security, science research and development, and systems engineering and integration. It provides technology-enabled business process, program management, and digital transformation solutions to U.S. government agencies, focusing on large-scale, technology-powered health and defense initiatives for agencies including HHS, VA, DoD, and their sub-agencies. Its revenues come from technology-enabled business process outsourcing, program management solutions, and public health research and analytics under time-and-materials, cost-reimbursable, and firm-fixed-price contracts.
DarioHealth Corp is a digital therapeutics (DTx) company delivering personalized evidence-based interventions that are driven by precision data analytics, software, and personalized coaching. The company vertically integrated a health intelligence platform with a mission to power the behavior changes that drive greater health. Unlike software-only digital health platforms, Dario owns the complete chain of value in chronic care management - connected FDA-cleared hardware devices that generate continuous physiological data, and AI built on that proprietary data. The company focuses on delivering user experiences, longer sustained engagement, and stronger clinical outcomes, at affordable prices, which then delivers the highest return on investment in the industry.